187 related articles for article (PubMed ID: 33926364)
21. Response to: 'Biologic discontinuation studies: a systematic review of methods' by van der Maas et al.
Yoshida K; Sung YK; Kavanaugh A; Bae SC; Weinblatt ME; Kishimoto M; Matsui K; Tohma S; Solomon DH
Ann Rheum Dis; 2014 Jan; 73(1):e5. PubMed ID: 24152418
[No Abstract] [Full Text] [Related]
22. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
Nagy G; van Vollenhoven RF
Arthritis Res Ther; 2015 Aug; 17(1):181. PubMed ID: 26235544
[TBL] [Abstract][Full Text] [Related]
23. Adherence to Anti-Tumor Necrosis Factor Therapy Administered Subcutaneously and Associated Factors in Patients With Rheumatoid Arthritis.
Salaffi F; Carotti M; Di Carlo M; Farah S; Gutierrez M
J Clin Rheumatol; 2015 Dec; 21(8):419-25. PubMed ID: 26587852
[TBL] [Abstract][Full Text] [Related]
24. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
25. Tailoring biologic therapy for real-world rheumatoid arthritis patients.
Romano C; Esposito S; Ferrara R; Cuomo G
Expert Opin Biol Ther; 2021 May; 21(5):661-674. PubMed ID: 33147106
[No Abstract] [Full Text] [Related]
26. Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis.
Koduri GM; Mukhtyar C
Rheumatology (Oxford); 2019 Apr; 58(4):559-560. PubMed ID: 29672739
[No Abstract] [Full Text] [Related]
27. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice.
Catay E; Bravo M; Rosa J; Soriano ER
BMC Musculoskelet Disord; 2016 Mar; 17():110. PubMed ID: 26932312
[TBL] [Abstract][Full Text] [Related]
29. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.
Asai S; Fujibayashi T; Oguchi T; Hanabayashi M; Hayashi M; Matsubara H; Ito T; Yabe Y; Watanabe T; Hirano Y; Kanayama Y; Kaneko A; Kato T; Takagi H; Takahashi N; Funahashi K; Takemoto T; Asai N; Watanabe T; Ishiguro N; Kojima T
Mod Rheumatol; 2018 Mar; 28(2):221-226. PubMed ID: 28701065
[TBL] [Abstract][Full Text] [Related]
30. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
Chen DY; Lau CS; Elzorkany B; Hsu PN; Praprotnik S; Vasilescu R; Marshall L; Llamado L
Int J Rheum Dis; 2018 Feb; 21(2):362-372. PubMed ID: 29205904
[TBL] [Abstract][Full Text] [Related]
31. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
[TBL] [Abstract][Full Text] [Related]
32. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
Tanaka Y; Hirata S
Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
[TBL] [Abstract][Full Text] [Related]
33. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Mary J; De Bandt M; Lukas C; Morel J; Combe B
J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
[TBL] [Abstract][Full Text] [Related]
34. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
Gu T; Mutebi A; Stolshek BS; Tan H
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
[TBL] [Abstract][Full Text] [Related]
35. New Rheumatoid Arthritis Treatments for 'Old' Patients: Results of a Systematic Review.
Caporali R; Fakhouri WKH; Nicolay C; Longley HJ; Losi S; Rogai V
Adv Ther; 2020 Sep; 37(9):3676-3691. PubMed ID: 32705531
[TBL] [Abstract][Full Text] [Related]
36. Treating to target in rheumatoid arthritis: biologic therapies.
Firth J; Critchley S
Br J Nurs; 2011 Nov 10-23; 20(20):1284, 1287-8, 1290-1. PubMed ID: 22068002
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
38. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation.
Iwamoto T; Ikeda K; Hosokawa J; Yamagata M; Tanaka S; Norimoto A; Sanayama Y; Nakagomi D; Takahashi K; Hirose K; Sugiyama T; Sueishi M; Nakajima H
Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1576-81. PubMed ID: 24515410
[TBL] [Abstract][Full Text] [Related]
39. The BeSt way of withdrawing biologic agents.
Allaart CF; Lems WF; Huizinga TW
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
[TBL] [Abstract][Full Text] [Related]
40. Experiences of mobility for people living with rheumatoid arthritis who are receiving biologic drug therapy: implications for podiatry services.
Sanders L; Donovan-Hall M; Borthwick A; Bowen CJ
J Foot Ankle Res; 2017; 10():14. PubMed ID: 28331550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
